AI-Enhanced Hyperspectral Imaging for Intraoperative Detection of Low-Grade Glioma: A Clinical Study
Organizations: imec, Kapeldreef 75, Leuven, 3001, Belgium · Department of Computer Science UAntwerp-imec, Sint-Pietersvliet 7, Antwerp, 2000, Belgium · Department of Telecommunications and Information Processing, IPI-imec, Sint-Pietersnieuwestraat 41, Ghent, 9000, Belgium · Carl Zeiss AG, Corporate Research & Technology, Carl-Zeiss-Str. 22, Oberkochen, 73447, Germany · Carl Zeiss Meditec AG, Rudolf-Eber-Str. 11, Oberkochen, 73447, Germany · Research Group Experimental Neurosurgery and Neuroanatomy, Dept Neurosciences, KU Leuven, Leuven Brain Institute and Dept. Neurosurgery, UZ Leuven, Herestraat 49, Leuven, 3000, Belgium
Abstract
Current image-guided neuronavigation techniques, such as intraoperative MRI and ultrasound, are limited by high costs, limited sensitivity and operational complexity. There is a clear need for more efficient systems to enhance intra-operative tumor detection and improve patient outcomes for intrinsic brain tumor resection. Whereas previous intraoperative brain HSI studies have predominantly investigated high-grade gliomas, glioblastomas, or mixed-grade cohorts, this clinical study focuses specifically on low-grade gliomas (LGGs). LGGs strongly resemble normal brain under white light conditions on the operative microscope. This study characterizes spectral differences between healthy and tumor tissue and provides a paired comparison of HSI- and RGB-based classification at matched tissue locations and under identical patient-level data splits. Tumor regions showed consistently lower reflectance, which may be associated with differences in hemoglobin concentration and oxygenation. A range of classification models was evaluated. The 3D CNN, which integrates spectral and spatial features, achieved the highest median ROC-AUC of 74.5%, compared with 67.9% for the spectral-only XGBoost model and 64.0% for the RGB-based model. These results support further investigation of HSI for low-grade glioma classification and quantify its performance relative to conventional RGB imaging in this cohort.
Figures & tables
| Specifications | InVivo-LGG | HELiCoiD [ 27 ] |
|---|---|---|
| Tumor types | LGG | Mix of brain tumors |
| Number of patients | 18 | 34 |
| Number of hypercubes | 75 | 61 |
| Maximum spatial resolution in pixels | ||
| Spectral range | 470–787 nm | 400–1000 nm |
| Spectral resolution | 10–15 nm | 2–3 nm |
| Models | #patients | F1 | ACC | b. ACC | AUC-ROC | PREC | RECALL |
|---|---|---|---|---|---|---|---|
| XGB | 16 | 0.68 0.09 | 0.68 0.06 | 0.68 0.06 | 0.68 0.06 | 0.68 0.13 | 0.74 0.08 |
| 2DCNN-All | 16 | 0.60 0.11 | 0.64 0.07 | 0.67 0.06 | 0.73 0.07 | 0.67 0.15 | 0.66 0.15 |
| 2DCNN-ch12 | 16 | 0.58 0.13 | 0.63 0.09 | 0.67 0.08 | 0.74 0.09 | 0.68 0.15 | 0.64 0.16 |
| 2DCNN-ch3 | 16 | 0.59 0.11 | 0.63 0.08 | 0.67 0.08 | 0.74 0.10 | 0.69 0.13 | 0.63 0.16 |
| 3DCNN | 16 | 0.64 0.10 | 0.66 0.08 | 0.69 0.07 | 0.75 0.08 | 0.69 0.13 | 0.70 0.14 |
| 2DCNN-RGB | 16 | 0.56 0.09 | 0.59 0.05 | 0.59 0.06 | 0.64 0.08 | 0.63 0.13 | 0.55 0.10 |
Appendix figures & tables3 assets
Supplementary material from the paper’s appendix.
Appendix
| Prediction | |||
|---|---|---|---|
| Positive | Negative | ||
| Ground truth | Positive | True positive (TP) | False Negative (FN) |
| Negative | False Positive (FP) | True Negative (TN) | |